GERN
Geron Corporation
$1.76
+$0.10(+6.02%)
45
Overall
60
Value
40
Tech
36
Quality
Market Cap
$695.81M
Volume
26.93M
52W Range
$1.04 - $2.01
Target Price
$3.40
Company Overview
| Mkt Cap | $695.81M | Price | $1.76 |
| Volume | 26.93M | Change | +6.02% |
| P/E Ratio | -4.0 | Open | $1.66 |
| Revenue | $77.0M | Prev Close | $1.66 |
| Net Income | $-174.6M | 52W Range | $1.04 - $2.01 |
| Div Yield | N/A | Target | $3.40 |
| Overall | 45 | Value | 60 |
| Quality | 36 | Technical | 40 |
No chart data available
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Geron Earnings Call: Rytelo Growth Amid Profit Pressures
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GERN | $1.76 | +6.0% | 26.93M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |